

## 9 - Chiropractic

Value	Root Operation	Definition/Explanation
B	Manipulation	<b>Definition:</b> Manual procedure that involves a directed thrust to move a joint past the physiological range of motion, without exceeding the anatomical limit

## X - New Technology

Value	Root Operation	Definition/Explanation
A	Assistance	<b>Definition:</b> Taking over a portion of a physiological function by extracorporeal means
5	Destruction	<b>Definition:</b> Physical eradication of all or a portion of a body part by the direct use of energy, force, or a destructive agent <b>Explanation:</b> None of the body part is physically taken out <b>Includes/Examples:</b> Fulguration of rectal polyp, cautery of skin lesion
7	Dilation	<b>Definition:</b> Expanding an orifice or the lumen of a tubular body part <b>Explanation:</b> The orifice can be a natural orifice or an artificially created orifice. Accomplished by stretching a tubular body part using intraluminal pressure or by cutting part of the orifice or wall of the tubular body part
C	Extirpation	<b>Definition:</b> Taking or cutting out solid matter from a body part <b>Explanation:</b> The solid matter may be an abnormal byproduct of a biological function or a foreign body; it may be imbedded in a body part or in the lumen of a tubular body part. The solid matter may or may not have been previously broken into pieces. <b>Includes/Examples:</b> Thrombectomy, choledocholithotomy
G	Fusion	<b>Definition:</b> Joining together portions of an articular body part rendering the articular body part immobile <b>Explanation:</b> The body part is joined together by fixation device, bone graft, or other means <b>Includes/Examples:</b> Spinal fusion, ankle arthrodesis
0	Introduction	<b>Definition:</b> Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
E	Measurement	<b>Definition:</b> Determining the level of a physiological or physical function at a point in time
2	Monitoring	<b>Definition:</b> Determining the level of a physiological or physical function repetitively over a period of time
1	Transfusion	<b>Definition:</b> Putting in blood or blood products
2	Transfusion	<b>Definition:</b> Putting in blood or blood products
R	Replacement	<b>Definition:</b> Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part <b>Explanation:</b> The body part may have been taken out or replaced, or may be taken out, physically eradicated, or rendered nonfunctional during the Replacement procedure. A Removal procedure is coded for taking out the device used in a previous replacement procedure. <b>Includes/Examples:</b> Total hip replacement, bone graft, free skin graft
S	Reposition	<b>Definition:</b> Moving to its normal location, or other suitable location, all or a portion of a body part <b>Explanation:</b> The body part is moved to a new location from an abnormal location, or from a normal location where it is not functioning correctly. The body part may or may not be cut out or off to be moved to the new location. <b>Includes/Examples:</b> Reposition of undescended testicle, fracture reduction
U	Supplement	<b>Definition:</b> Putting in or on biological or synthetic material that physically reinforces and/or augments the function of a portion of a body part

**X:** New Technology  
**W:** Anatomical Regions

Operation-Character 3	Body Part-Character 4	Approach-Character 5	Device-Character 6	Qualifier-Character 7
0 Introduction	1 Subcutaneous Tissue	3 Percutaneous	0 Brexanolone	1 New Technology Group 1
1 Transfusion	2 Muscle	7 Via Natural or Artificial Opening	2 Plasma, Convalescent (Nonautologous)	2 New Technology Group 2
2 Transfusion	3 Peripheral Vein	8 Via Natural or Artificial Opening Endoscopic	1 Eladocogene exuparvovec	3 New Technology Group 3
	4 Central Vein	X External	2 Ceftazidime-Avibactam Anti-infective	4 New Technology Group 4
	9 Nose		2 Nerinitide	5 New Technology Group 5
	D Mouth and Pharynx		3 Idarucizumab, Dabigatran Reversal Agent	6 New Technology Group 6
	G Upper GI		3 Durvalumab Antineoplastic	
	H Lower GI		4 Brexucabtagene Autoleucel Immunotherapy	
	Q Cranial Cavity and Brain		4 Isavuconazole Antiinfective	
			5 Blinatumomab Antineoplastic Immunotherapy	
			6 Lefamulin Anti-infective	
			7 Coagulation Factor Xa, Inactivated	
			7 Lisocabtagene Maraleucel Immunotherapy	
			8 Mineral-based Topical Hemostatic Agent	
			8 Uridine Triacetate	
			9 Defibrotide Sodium Anticoagulant	
			9 Ceftolozane/Tazobactam Anti-infective	
			A Bezlotoxumab Monoclonal Antibody	
			A Cefiderocol Anti-infective	
			B Cytarabine and Daunorubicin Liposome Antineoplastic	
			B Omadacycline Anti-infective	
			C Eculizumab	
			C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy	
			D Atezolizumab Antineoplastic	
			E Etesevimab Monoclonal Antibody	
			E Remdesivir Anti-infective	
			F Bamlanivimab Monoclonal Antibody	
			F Other New Technology Therapeutic Substance	
			G Plazomicin Anti-infective	
			G REGN-COV2 Monoclonal Antibody	
			G Sarilumab	
			H Other New Technology Monoclonal Antibody	

Table continued on next page

**Appendix E: Character Meaning**

**X:** New Technology  
**W:** Anatomical Regions

Table continued from previous page

<b>Operation-Character 3</b>	<b>Body Part-Character 4</b>	<b>Approach-Character 5</b>	<b>Device-Character 6</b>	<b>Qualifier-Character 7</b>
			<b>H</b> Synthetic Human Angiotensin II	
			<b>H</b> Tocilizumab	
			<b>J</b> Apalutamide Antineoplastic	
			<b>K</b> Fosfomycin Anti-infective	
			<b>K</b> Leronlimab Monoclonal Antibody	
			<b>L</b> CD24Fc Immunomodulator	
			<b>L</b> Erdaftinib Antineoplastic	
			<b>M</b> Baricitinib	
			<b>M</b> Esketamine Hydrochloride	
			<b>N</b> Meropenem-vaborbactam Anti-infective	
			<b>Q</b> Tagraxofusp-erzs Antineoplastic	
			<b>R</b> Venetoclax Antineoplastic	
			<b>S</b> COVID-19 Vaccine Dose 1	
			<b>S</b> Iobenguane I-131 Antineoplastic	
			<b>T</b> COVID-19 Vaccine Dose 2	
			<b>T</b> Ruxolitinib	
			<b>U</b> COVID-19 Vaccine	
			<b>U</b> Imipenem-cilastatin-relebactam Anti-infective	
			<b>V</b> Gilteritinib Antineoplastic	
			<b>W</b> Caplacizumab	

**X:** New Technology  
**X:** Physiological Systems

<b>Operation-Character 3</b>	<b>Body Part-Character 4</b>	<b>Approach-Character 5</b>	<b>Device-Character 6</b>	<b>Qualifier-Character 7</b>
<b>E</b> Measurement	<b>5</b> Circulatory	<b>X</b> External	<b>M</b> Infection, Whole Blood Nucleic Acid-base Microbial Detection	<b>5</b> New Technology Group 5
	<b>B</b> Respiratory		<b>N</b> Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility	<b>6</b> New Technology Group 6
			<b>Q</b> Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection	

**X:** New Technology  
**Y:** Extracorporeal

<b>Operation-Character 3</b>	<b>Body Part-Character 4</b>	<b>Approach-Character 5</b>	<b>Device-Character 6</b>	<b>Qualifier-Character 7</b>
<b>0</b> Introduction	<b>V</b> Vein Graft	<b>X</b> External	<b>8</b> Endothelial Damage Inhibitor	<b>3</b> New Technology Group 3

## Appendix F: Substance Key

Substance Term	ICD-10-PCS Value
ACTEMRA®	Tocilizumab
AIGISRx® Antibacterial Envelope	Anti-Infective Envelope
Andexanet Alfa, Factor Xa Inhibitor Reversal Agent	Coagulation Factor Xa, Inactivated
Andexxa®	Coagulation Factor Xa, Inactivated
Angiotensin II	Synthetic Human Angiotensin II
Antibacterial Envelope (TYRX™) (AIGISRx™)	Anti-Infective Envelope
Antimicrobial Envelope	Anti-Infective Envelope
Axicabtagene Ciloeucel	Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy
AZEDRA®	lobenguane I-131 Antineoplastic
Bone morphogenetic protein 2 (BMP 2)	Recombinant Bone Morphogenetic Protein
Brexucabtagene Autoleucel	Brexucabtagene Autoleucel Immunotherapy
CBMA (Concentrated Bone Marrow Aspirate)	Concentrated Bone Marrow Aspirate
Clolar®	Clofarabine
Coagulation Factor Xa, (Recombinant) Inactivated	Coagulation Factor Xa, Inactivated
CONTEPO™	Fosfomycin Anti-infective
Defitelio®	Defibrotide Sodium Anticoagulant
DuraGraft® Endothelial Damage Inhibitor	Endothelial Damage Inhibitor
ELZONRIS™	Tagraxofusp-erzs Antineoplastic
ERLEADA™	Apalutamide Antineoplastic
Factor Xa Inhibitor Reversal Agent, Andexanet Alfa	Coagulation Factor Xa, Inactivated
FETROJA®	Cefiderocol Anti-infective
Fosfomycin injection	Fosfomycin Anti-infective
GIAPREZA™	Synthetic Human Angiotensin II
GS-5734	Remdesivir Anti-infective
Hemospray® Endoscopic Hemostat	Mineral-based Topical Hemostatic Agent
Human angiotensin II, synthetic	Synthetic Human Angiotensin II
IMFINZI®	Durvalumab Antineoplastic
IMI/REL	Imipenem-cilastatin-relebactam Anti-infective
lobenguane I-131, High Specific Activity (HSA)	lobenguane I-131 Antineoplastic
Jakafi®	Ruxolitinib
Kcentra®	4-Factor Prothrombin Complex Concentrate
KEVZARA®	Sarilumab
KYMRIAH®	Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy
Lisocabtagene Maraleucel	Lisocabtagene Maraleucel Immunotherapy
NA-1 (Nerinitide)	Nerinitide
Nesiritide®	Human B-type Natriuretic Peptide
NUZYRA™	Omadacycline Anti-infective
OTL-101	Hematopoietic Stem/Progenitor Cells, Genetically Modified
rhBMP-2	Recombinant Bone Morphogenetic Protein
Septrafilm®	Adhesion Barrier
Soliris®	Eculizumab
SPRAVATO™	Esketamine Hydrochloride
STELARA®	Other New Technology Therapeutic Substance

Substance Term	ICD-10-PCS Value
TECENTRIQ®	Atezolizumab Antineoplastic
Tisagenlecleucel	Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy
Tissue Plasminogen Activator (tPA)(r- tPA)	Other Thrombolytic
TYRX™ Antibacterial Envelope	Anti-Infective Envelope
Ustekinumab	Other New Technology Therapeutic Substance
Vabomere™	Meropenem-vaborbactam Anti-infective
Veklury	Remdesivir Anti-infective
Venclexta®	Venetoclax Antineoplastic
Vistogard®	Uridine Triacetate
Voraxaze®	Glucarpidase
VYXEOS™	Cytarabine and Daunorubicin Liposome Antineoplastic
XENLETA™	Lefamulin Anti-infective
XOSPATA®	Gilteritinib Antineoplastic
ZERBAXA®	Ceftolozane/Tazobactam Anti-infective
ZINPLAVA™	Bezlotoxumab Monoclonal Antibody
ZULRESSO™	Brexanolone
Zyvox®	Oxazolidinones